Furthermore, gain-of-function mutations in IDH1 and IDH2 have been discovered in several cancers, and IDH inhibitors, including ivosidenib (AG-120) and enasidenib (AG-221), are now clinically available for treatment of cancers with IDH mutations [17]. The gene discussed is IDH2; the disease is cancer.